As every year for 12 years, a list of drugs to avoid has been drawn up by the specialist journal Prescrire, whose stated objective is to“avoiding disproportionate harm to patients”.
Written by a panel of health professionals, this list includes this year 107 drugs, considered ineffective or dangerous.
“Certain drugs are added, others are withdrawn, either because their marketing has been stopped by decision of the company or a health authority, or until Prescrire re-examines their benefit-risk balance, likely to be modified by new data being analyzed”, says the review.
Of these 107 drugs, 88 are marketed in France.
Three new pharmaceuticals are entering this 2023 list: peanut protein, roxadustat, tincture of opium:
Generally used for the treatment of certain bronchial cancers, nintedanib, a drug for which all risks had been ruled out in 2021, was nevertheless added to the list.“Analysis of clinical evaluation data showed that […] the benefit-risk balance of nintedanib is unfavourable. It is therefore once more among the drugs to be ruled out”, details the review.
Two drugs were withdrawn from the balance sheet for reassessment: idebenone and teriflunomide.
